NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) Screening Protocol
Latest Information Update: 09 Sep 2024
At a glance
- Drugs Ensartinib (Primary) ; Erdafitinib (Primary) ; Larotrectinib (Primary) ; Larotrectinib (Primary) ; Olaparib (Primary) ; Palbociclib (Primary) ; Samotolisib (Primary) ; Selpercatinib (Primary) ; Selumetinib (Primary) ; Tazemetostat (Primary) ; Tipifarnib (Primary) ; Tipifarnib (Primary) ; Ulixertinib (Primary) ; Vemurafenib (Primary)
- Indications CNS cancer; Ependymoma; Ewing's sarcoma; Germ cell and embryonal neoplasms; Germ cell cancer; Glioma; Hepatoblastoma; Langerhans cell histiocytosis; Lymphoma; Neuroblastoma; Non-Hodgkin's lymphoma; Osteosarcoma; Rhabdomyosarcoma; Soft tissue sarcoma; Solid tumours; Wilms' tumour
- Focus Therapeutic Use
- Acronyms Pediatric MATCH
- 06 Jun 2023 Trial design presented at the 59th Annual Meeting of the American Society of Clinical Oncology
- 01 Apr 2022 Results from arm E (n=20) published in the Journal of Clinical Oncology
- 08 Mar 2022 Status changed from suspended to recruiting.